# A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

> **NCT06758557** · PHASE1,PHASE2 · RECRUITING · sponsor: **Huabo Biopharm Co., Ltd.** · enrollment: 282 (estimated)

## Conditions studied

- Advanced NSCLC
- Advanced Endometrial Cancer

## Interventions

- **DRUG:** HB0025
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06758557
- **Lead sponsor:** Huabo Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06758557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06758557, "A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06758557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*